RT Journal Article
SR Electronic
T1 The incidence of COVID-19-related hospitalisation in migrants in the UK: Findings from the Virus Watch prospective community cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.06.22283653
DO 10.1101/2023.01.06.22283653
A1 Fong, Wing Lam Erica
A1 Nguyen, Vincent G
A1 Burns, Rachel
A1 Boukari, Yamina
A1 Beale, Sarah
A1 Braithwaite, Isobel
A1 Byrne, Thomas E
A1 Geismar, Cyril
A1 Fragaszy, Ellen
A1 Hoskins, Susan
A1 Kovar, Jana
A1 Navaratnam, Annalan MD
A1 Oskrochi, Youssof
A1 Patel, Parth
A1 Tweed, Sam
A1 Yavlinsky, Alexei
A1 Hayward, Andrew C
A1 Aldridge, Robert W
YR 2023
UL http://medrxiv.org/content/early/2023/01/07/2023.01.06.22283653.abstract
AB Background Migrants in the UK may be at higher risk of SARS-CoV-2 exposure; however, little is known about their risk of COVID-19-related hospitalisation during waves 1-3 of the pandemic.Methods We analysed secondary care data linked to Virus Watch study data for adults and estimated COVID-19-related hospitalisation incidence rates by migration status. To estimate the total effect of migration status on COVID-19 hospitalisation rates, we ran fixed-effect Poisson regression for wave 1 (01/03/2020-31/08/2020; wildtype), and fixed-effect negative binomial regressions for waves 2 (01/09/2020-31/05/2021; Alpha) and 3 (01/06/2020-31/11/2021; Delta). Results of all models were then meta-analysed.Results Of 30,276 adults in the analyses, 26,492 (87.5%) were UK-born and 3,784 (12.5%) were migrants. COVID-19-related hospitalisation incidence rates for UK-born and migrant individuals across waves 1-3 were 2.7 [95% CI 2.2-3.2], and 4.6 [3.1-6.7] per 1,000 person-years, respectively. Pooled incidence rate ratios across waves suggested increased rate of COVID-19-related hospitalisation in migrants compared to UK-born individuals in unadjusted 1.68 [1.08-2.60] and adjusted analyses 1.35 [0.71-2.60].Conclusion Our findings suggest migration populations in the UK have excess risk of COVID-19-related hospitalisations and underscore the need for more equitable interventions particularly aimed at COVID-19 vaccination uptake among migrants.Competing Interest StatementACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. RB has received funding from Doctors of the World (DOTW) and is the chair of the DOTW Refugee and Migrant Health Research Consortium. YB's spouse is employed by Elsevier as a Software Engineer. The other authors declare no potential conflict of interests.Funding StatementThis work was supported by the Medical Research Council [Grant Ref: MC_PC 19070] awarded to UCL on 30 March 2020 and Medical Research Council [Grant Ref: MR/V028375/1] awarded on 17 August 2020. The study also received $15,000 of advertising credit from Facebook to support a pilot social media recruitment campaign on 18th August 2020. This study was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RWA [206602]. IB is supported by an NIHR Academic Clinical Fellowship. SB and TB are supported by an MRC doctoral studentship (MR/N013867/1). From 1 May 2022 Virus Watch received funding from the European Union (Project: 101046314). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Virus Watch study was approved by the Hampstead NHS Health Research Authority Ethics Committee: 20/HRA/2320, and conformed to the ethical standards set out in the Declaration of Helsinki. All participants provided informed consent for all aspects of the study. Approval was also obtained from the Independent Group Advising on the Release of Data (IGARD) to use the NHS Digital data under DSA DARS-NIC-372269-N8D7Z-v1.6I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the Virus Watch cohort are available on ONS Secure Research Service. The data are available under restricted access as they contain sensitive health data. Access can be obtained by ONS Secure Research Service.